Oxymorphone (BioDeep_00000001508)

 

Secondary id: BioDeep_00000405972

human metabolite Endogenous blood metabolite


代谢物信息卡片


(1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one

化学式: C17H19NO4 (301.1314014)
中文名称: 氢羟吗啡酮
谱图信息: 最多检出来源 Homo sapiens(blood) 0.45%

分子结构信息

SMILES: CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O
InChI: InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1

描述信息

An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AA - Natural opium alkaloids
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist
D002491 - Central Nervous System Agents > D000700 - Analgesics

同义名列表

16 个代谢物同义名

(1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one; Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5.alpha.)-; Bristol-myers squibb brand OF oxymorphone hydrochloride; endo Brand OF oxymorphone hydrochloride; endo Brand OF oxymorphine HCL; 14-Hydroxydihydromorphinone; Oxymorphone hydrochloride; Dihydrohydroxymorphinone; Dihydroxymorphinone; Oxymorphone HCL; Oximorphonum; Oxymorphine; oxymorphone; Numorphan; EN3202; Opana



数据库引用编号

17 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Nicole Arguelles, Janielle Richards, Ahmed A El-Sherbeni, Sharon Miksys, Rachel F Tyndale. Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia. Biochemical pharmacology. 2022 04; 198(?):114949. doi: 10.1016/j.bcp.2022.114949. [PMID: 35143755]
  • Michael T Truver, Gerd Jakobsson, Maria D Chermà, Madeleine J Swortwood, Henrik Gréen, Robert Kronstrand. The Quantification of Oxycodone and Its Phase I and II Metabolites in Urine. Journal of analytical toxicology. 2022 Feb; 46(1):55-63. doi: 10.1093/jat/bkaa186. [PMID: 33270113]
  • Aymen A Al-Qurain, Desmond B Williams, Lorraine Mackenzie, Michael S Roberts, Michael D Wiese. Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling. Journal of pharmaceutical and biomedical analysis. 2021 Sep; 203(?):114171. doi: 10.1016/j.jpba.2021.114171. [PMID: 34087551]
  • John R Cashman, Mark Gohdes, Annelies de Kater, Grant Schoenhard. N-Oxygenation of Oxycodone and Retro-reduction of Oxycodone N-Oxide. Drug metabolism and disposition: the biological fate of chemicals. 2020 02; 48(2):106-115. doi: 10.1124/dmd.119.089300. [PMID: 31727673]
  • Mari Kinnunen, Hannu Kokki, Heidi Hautajärvi, Juulia Lantto, Juha Räsänen, Hanna-Marja Voipio, Merja Kokki. Oxycodone concentrations in the central nervous system and cerebrospinal fluid after epidural administration to the pregnant ewe. Basic & clinical pharmacology & toxicology. 2019 Nov; 125(5):430-438. doi: 10.1111/bcpt.13276. [PMID: 31222944]
  • Anne Leuppi-Taegtmeyer, Urs Duthaler, Felix Hammann, Yasmin Schmid, Michael Dickenmann, Patricia Amico, Andreas W Jehle, Stefan Kalbermatter, Christoph Lenherr, Henriette E Meyer Zu Schwabedissen, Manuel Haschke, Matthias E Liechti, Stephan Krähenbühl. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2019 04; 34(4):692-702. doi: 10.1093/ndt/gfy285. [PMID: 30189012]
  • Robert West, Charles Mikel, Doriane Hofilena, Maria Guevara. Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS. Drug and alcohol dependence. 2018 12; 193(?):183-191. doi: 10.1016/j.drugalcdep.2018.07.023. [PMID: 30391868]
  • Alex K Bonnecaze, Matthew W Wilson, Ajay Dharod, Alison Fletcher, Peter John Miller. Acute kidney injury is common with intravenous abuse of extended-release oral oxymorphone and delayed renal recovery rates are associated with increased KDIGO staging. Nephrology (Carlton, Vic.). 2018 Oct; 23(10):921-926. doi: 10.1111/nep.13153. [PMID: 28802086]
  • T Sobolevsky, Y Kucherova, B Ahrens. Identification of oxymorphone as decomposition product of the permitted drug methylnaltrexone. Drug testing and analysis. 2018 May; 10(5):892-895. doi: 10.1002/dta.2353. [PMID: 29314653]
  • Michele Protti, Maria Carmen Catapano, Boaz Gedaliahu Samolsky Dekel, James Rudge, Gilberto Gerra, Lorenzo Somaini, Roberto Mandrioli, Laura Mercolini. Determination of oxycodone and its major metabolites in haematic and urinary matrices: Comparison of traditional and miniaturised sampling approaches. Journal of pharmaceutical and biomedical analysis. 2018 Apr; 152(?):204-214. doi: 10.1016/j.jpba.2018.01.043. [PMID: 29414014]
  • Yan Yatsynovich, Dmitri Souza, Natallia Maroz. Oxymorphone Hydrochloride Extended-Release (OPANA®) Associated With Acute Kidney Injury in a Chronic Pain Patient: A Case Report. A & A case reports. 2017 Dec; 9(11):324-327. doi: 10.1213/xaa.0000000000000607. [PMID: 28786851]
  • Paul D Gavin, Lee S Simon, Thomas Schlagheck, Alisha J Smith, Janakan Krishnarajah. A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system. Pain management. 2017 Nov; 7(6):499-512. doi: 10.2217/pmt-2017-0032. [PMID: 28814158]
  • Flaminia Pantano, Stefano Brauneis, Alexandre Forneris, Roberta Pacifici, Enrico Marinelli, Chrystalla Kyriakou, Simona Pichini, Francesco Paolo Busardò. Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases. Clinical chemistry and laboratory medicine. 2017 Aug; 55(9):1324-1331. doi: 10.1515/cclm-2016-0990. [PMID: 28080998]
  • Boaz Gedaliahu Samolsky Dekel, Gabriele Donati, Alessio Vasarri, Anna Laura Croci Chiocchini, Alberto Gori, Giuseppe Cavallari, Gianfranco Di Nino, Laura Mercolini, Michele Protti, Roberto Mandrioli, Rita Maria Melotti, Gaetano La Manna. Dialyzability of Oxycodone and Its Metabolites in Chronic Noncancer Pain Patients with End-Stage Renal Disease. Pain practice : the official journal of World Institute of Pain. 2017 06; 17(5):604-615. doi: 10.1111/papr.12483. [PMID: 27589376]
  • Amibhen Gandhi, Saad Ullah, Shani Kotadia, Samer Nasser. Oxymorphone Induced Thrombotic Microangiopathy Mimicking Atypical Haemolytic Uremic Syndrome. Journal of Ayub Medical College, Abbottabad : JAMC. 2017 Apr; 29(2):360-362. doi: . [PMID: 28718268]
  • Matthew W Wilson, Alex K Bonnecaze, Ajay Dharod, Peter J Miller. Analysis of Intensive Care Unit Admission and Sequelae in Patients Intravenously Abusing Extended-Release Oral Oxymorphone. Southern medical journal. 2017 03; 110(3):217-222. doi: 10.14423/smj.0000000000000624. [PMID: 28257549]
  • Ryan Hunt, Ayla Yalamanoglu, James Tumlin, Tal Schiller, Jin Hyen Baek, Andrew Wu, Agnes B Fogo, Haichun Yang, Edward Wong, Peter Miller, Paul W Buehler, Chava Kimchi-Sarfaty. A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood. 2017 02; 129(7):896-905. doi: 10.1182/blood-2016-08-736579. [PMID: 27864296]
  • Robert B Dixon, Amitava Dasgupta. Suitability of the DRI Hydrocodone/Hydromorphone Immunoassay in the Clinical Environment at a Lower Cutoff: Validation With LC-MS/MS Analysis. Therapeutic drug monitoring. 2016 12; 38(6):787-790. doi: 10.1097/ftd.0000000000000339. [PMID: 27764026]
  • Pongkwan Sitasuwan, Cathleen Melendez, Margarita Marinova, Kaylee R Mastrianni, Alicia Darragh, Emily Ryan, L Andrew Lee. Degradation of Opioids and Opiates During Acid Hydrolysis Leads to Reduced Recovery Compared to Enzymatic Hydrolysis. Journal of analytical toxicology. 2016 Oct; 40(8):601-607. doi: 10.1093/jat/bkw085. [PMID: 27702939]
  • Anne Z DePriest, Rebecca Heltsley, David L Black, John M Mitchell, Charles LoDico, Ronald Flegel, Edward J Cone. Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration. Journal of analytical toxicology. 2016 Oct; 40(8):566-574. doi: 10.1093/jat/bkw064. [PMID: 27405370]
  • Eric T Shimomura, Alice J Briones, Wendy S Warren, Joseph W Addison, Jessica L Knittel, Sarah A Shoemaker, Taj D King, Thomas Z Bosy. Case Report of Methylone, Oxymorphone and Ethanol in a Fatality Case with Tissue Distribution. Journal of analytical toxicology. 2016 Sep; 40(7):543-5. doi: 10.1093/jat/bkw045. [PMID: 27405363]
  • Waseem Gul, Brandon Stamper, Murrell Godfrey, Shahbaz W Gul, Mahmoud A ElSohly. LC-MS-MS Method for Analysis of Opiates in Wastewater During Football Games II. Journal of analytical toxicology. 2016 Jun; 40(5):330-7. doi: 10.1093/jat/bkw022. [PMID: 27052850]
  • Fleur Gaudette, Andréa Sirhan-Daneau, Maude St-Onge, Jacques Turgeon, Veronique Michaud. Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2016 Jan; 1008(?):174-180. doi: 10.1016/j.jchromb.2015.11.035. [PMID: 26655109]
  • Cynthia M Magro, Aixa Toledo-Garcia, Ozlem Pala, Shabnam Momtahen, Lee Shapiro. Opioid associated intravenous and cutaneous microvascular drug abuse (skin-popping) masquerading as Degos disease (malignant atrophic papulosis) with multiorgan involvement. Dermatology online journal. 2015 09; 21(9):. doi: . [PMID: 26437280]
  • Deepali Gangahar. A case of rhabdomyolysis associated with severe opioid withdrawal. The American journal on addictions. 2015 Aug; 24(5):400-2. doi: 10.1111/ajad.12255. [PMID: 26095066]
  • Lisa E MacDonald, Jennifer E Onsrud, Rita Mullins-Hodgin. Acute Sensorineural Hearing Loss After Abuse of an Inhaled, Crushed Oxymorphone Extended-Release Tablet. Pharmacotherapy. 2015 Jul; 35(7):e118-21. doi: 10.1002/phar.1605. [PMID: 26112082]
  • Natalie M Elder, Rabia S Atayee, Brookie M Best, Joseph D Ma. Response to urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions. Journal of analytical toxicology. 2015 Jan; 39(1):80. doi: 10.1093/jat/bku112. [PMID: 25288719]
  • Gerd Mikus. Urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions?. Journal of analytical toxicology. 2015 Jan; 39(1):81-2. doi: 10.1093/jat/bku111. [PMID: 25288721]
  • Peter L Platteborze, Donald J Kippenberger, Thomas M Martin. Unauthorized drug use in the US Army based on medical review officer evaluations. Journal of analytical toxicology. 2014 Nov; 38(9):653-9. doi: 10.1093/jat/bku079. [PMID: 25002456]
  • Anne Z DePriest, Brandi L Puet, Rebecca Heltsley, Timothy Robert, David L Black. Uncertainty in assessing impact of drug-drug interactions on oxycodone metabolite patterns. Journal of analytical toxicology. 2014 Sep; 38(7):462. doi: 10.1093/jat/bku071. [PMID: 24986837]
  • Natalie M Elder, Rabia S Atayee, Brookie M Best, Joseph D Ma. Authors' reply. Journal of analytical toxicology. 2014 Sep; 38(7):463. doi: 10.1093/jat/bku074. [PMID: 24986838]
  • Peter John Miller, Andrew Matthew Farland, Mary Ann Knovich, Katharine Marie Batt, John Owen. Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange. American journal of hematology. 2014 Jul; 89(7):695-7. doi: 10.1002/ajh.23720. [PMID: 24668845]
  • Josephine M Ambruzs, Paul B Serrell, Naeem Rahim, Christopher P Larsen. Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014 Jun; 63(6):1022-6. doi: 10.1053/j.ajkd.2014.01.015. [PMID: 24529995]
  • Natalie M Elder, Rabia S Atayee, Brookie M Best, Joseph D Ma. Observations of urinary oxycodone and metabolite distributions in pain patients. Journal of analytical toxicology. 2014 Apr; 38(3):129-34. doi: 10.1093/jat/bku007. [PMID: 24523296]
  • Guang-Tao Hao, Hai-Yan Zhou, Hong-Zhi Gao, Heng-Yan Qu, Yu-Guang Liang, Yuan-Yuan Li, Rui-Hua Dong, Li-Juan Zhang, Xiao-Fang Wang, Ze-Yuan Liu. Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. Pharmacological reports : PR. 2014 Feb; 66(1):153-8. doi: 10.1016/j.pharep.2013.08.012. [PMID: 24905321]
  • Egilius L H Spierings, Edmund R Volkerts, Ivo Heitland, Heather Thomson. A randomized, rater-blinded, crossover study of the effects of oxymorphone extended release, fed versus fasting, on cognitive performance as tested with CANTAB in opioid-tolerant subjects. Pain medicine (Malden, Mass.). 2014 Feb; 15(2):264-71. doi: 10.1111/pme.12307. [PMID: 24330343]
  • Kathleen V Moy, Joseph D Ma, Candis M Morello, Rabia S Atayee, Brookie M Best. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine. Journal of opioid management. 2014 Jan; 10(1):47-56. doi: 10.5055/jom.2014.0191. [PMID: 24604569]
  • Yutaka Fujiwara, Masanori Toyoda, Naoko Chayahara, Naomi Kiyota, Takanobu Shimada, Yoshinori Imamura, Toru Mukohara, Hironobu Minami. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. PloS one. 2014; 9(8):e104215. doi: 10.1371/journal.pone.0104215. [PMID: 25121773]
  • Ali Imran Amjad, Rahul A Parikh. Opana-ER used the wrong way: intravenous abuse leading to microangiopathic hemolysis and a TTP-like syndrome. Blood. 2013 Nov; 122(20):3403. doi: 10.1182/blood-2013-05-503904. [PMID: 24369032]
  • Muhammad Waqas Sadiq, Emma Boström, Ron Keizer, Sven Björkman, Margareta Hammarlund-Udenaes. Oxymorphone active uptake at the blood-brain barrier and population modeling of its pharmacokinetic-pharmacodynamic relationship. Journal of pharmaceutical sciences. 2013 Sep; 102(9):3320-31. doi: 10.1002/jps.23492. [PMID: 23463542]
  • Lesley J Smith, Butch K Kukanich, Lisa A Krugner-Higby, Brynn H Schmidt, Timothy D Heath. Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs. Veterinary anaesthesia and analgesia. 2013 Sep; 40(5):537-45. doi: 10.1111/vaa.12042. [PMID: 23601353]
  • Takafumi Naito, Masaki Tashiro, Takuya Ishida, Kazunori Ohnishi, Junichi Kawakami. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients. Journal of clinical pharmacology. 2013 Aug; 53(8):812-8. doi: 10.1002/jcph.112. [PMID: 23733622]
  • Wenfang B Fang, Michelle R Lofwall, Sharon L Walsh, David E Moody. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications. Journal of analytical toxicology. 2013 Jul; 37(6):337-44. doi: 10.1093/jat/bkt042. [PMID: 23743505]
  • Jessica M Colón-Franco, Elbert T Cox, David B Crosby, Sheila Dawling. Resolution of an apparent hook effect in Roche partner DRI oxycodone immunoassay. Journal of analytical toxicology. 2013 Jul; 37(6):376-81. doi: 10.1093/jat/bkt044. [PMID: 23711948]
  • Edward J Cone, Rebecca Heltsley, David L Black, John M Mitchell, Charles P Lodico, Ronald R Flegel. Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration. Journal of analytical toxicology. 2013 Jun; 37(5):255-64. doi: 10.1093/jat/bkt031. [PMID: 23609023]
  • Ulrike M Stamer, Lan Zhang, Malte Book, Lutz E Lehmann, Frank Stuber, Frank Musshoff. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. PloS one. 2013; 8(3):e60239. doi: 10.1371/journal.pone.0060239. [PMID: 23555934]
  • Joseph V Pergolizzi, Robert B Raffa, Robert Taylor, Swati Nagar, Sumedha Labhsetwar, Nicholas Sinclair, Errol M Gould. An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult. Journal of opioid management. 2012 Nov; 8(6):383-93. doi: 10.5055/jom.2012.0138. [PMID: 23264316]
  • Jane A Dickerson, Thomas J Laha, Monica B Pagano, Brendan R O'Donnell, Andrew N Hoofnagle. Improved detection of opioid use in chronic pain patients through monitoring of opioid glucuronides in urine. Journal of analytical toxicology. 2012 Oct; 36(8):541-7. doi: 10.1093/jat/bks063. [PMID: 22833646]
  • Wuyi Zha, Linyee Shum. Simultaneous determination of oxymorphone and its active metabolite 6-OH-oxymorphone in human plasma by high performance liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Aug; 902(?):116-21. doi: 10.1016/j.jchromb.2012.06.035. [PMID: 22795571]
  • M Pravetoni, M D Raleigh, M Le Naour, A M Tucker, T M Harmon, J M Jones, A K Birnbaum, P S Portoghese, P R Pentel. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine. 2012 Jun; 30(31):4617-24. doi: 10.1016/j.vaccine.2012.04.101. [PMID: 22583811]
  • James Tuyay, Cynthia Coulter, Warren Rodrigues, Christine Moore. Disposition of opioids in oral fluid: Importance of chromatography and mass spectral transitions in LC-MS/MS. Drug testing and analysis. 2012 Jun; 4(6):395-401. doi: 10.1002/dta.1324. [PMID: 22374679]
  • David A Yee, Brookie M Best, Rabia S Atayee, Amadeo J Pesce. Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients. Journal of analytical toxicology. 2012 May; 36(4):232-8. doi: 10.1093/jat/bks022. [PMID: 22511697]
  • Trine Naalsund Andreassen, Pål Klepstad, Andrew Davies, Kristin Bjordal, Staffan Lundström, Stein Kaasa, Ola Dale. Is oxycodone efficacy reflected in serum concentrations? A multicenter, cross-sectional study in 456 adult cancer patients. Journal of pain and symptom management. 2012 Apr; 43(4):694-705. doi: 10.1016/j.jpainsymman.2011.05.008. [PMID: 22285284]
  • K T Siao, B H Pypendop, A Escobar, S D Stanley, J E Ilkiw. Effect of amantadine on oxymorphone-induced thermal antinociception in cats. Journal of veterinary pharmacology and therapeutics. 2012 Apr; 35(2):169-74. doi: 10.1111/j.1365-2885.2011.01305.x. [PMID: 21535013]
  • M Pravetoni, M Le Naour, T M Harmon, A M Tucker, P S Portoghese, P R Pentel. An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. The Journal of pharmacology and experimental therapeutics. 2012 Apr; 341(1):225-32. doi: 10.1124/jpet.111.189506. [PMID: 22262924]
  • Kuntheavy Ing Lorenzini, Youssef Daali, Pierre Dayer, Jules Desmeules. Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview. Basic & clinical pharmacology & toxicology. 2012 Mar; 110(3):219-26. doi: 10.1111/j.1742-7843.2011.00814.x. [PMID: 21995512]
  • Rebecca Heltsley, Anne Depriest, David L Black, Dennis J Crouch, Tim Robert, Lucas Marshall, Viola M Meadors, Yale H Caplan, Edward J Cone. Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens. Journal of analytical toxicology. 2012 Mar; 36(2):75-80. doi: 10.1093/jat/bkr019. [PMID: 22337775]
  • William D Fiske, Janet Jobes, Qinfang Xiang, Sou-Chan Chang, Irma H Benedek. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets. The journal of pain. 2012 Jan; 13(1):90-9. doi: 10.1016/j.jpain.2011.10.011. [PMID: 22208805]
  • Trine Naalsund Andreassen, Ingrid Eftedal, Pål Klepstad, Andrew Davies, Kristin Bjordal, Staffan Lundström, Stein Kaasa, Ola Dale. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. European journal of clinical pharmacology. 2012 Jan; 68(1):55-64. doi: 10.1007/s00228-011-1093-5. [PMID: 21735164]
  • Deborah French, Alan Wu, Kara Lynch. Hydrophilic interaction LC-MS/MS analysis of opioids in urine: significance of glucuronide metabolites. Bioanalysis. 2011 Dec; 3(23):2603-12. doi: 10.4155/bio.11.266. [PMID: 22136049]
  • K T Siao, B H Pypendop, S D Stanley, J E Ilkiw. Pharmacokinetics of oxymorphone in cats. Journal of veterinary pharmacology and therapeutics. 2011 Dec; 34(6):594-8. doi: 10.1111/j.1365-2885.2011.01271.x. [PMID: 21323677]
  • Takafumi Naito, Yoshiaki Takashina, Keisuke Yamamoto, Masaki Tashiro, Kazunori Ohnishi, Yoshiyuki Kagawa, Junichi Kawakami. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. Journal of clinical pharmacology. 2011 Nov; 51(11):1529-38. doi: 10.1177/0091270010388033. [PMID: 21209234]
  • Gobi Paramanandam, Eric Prommer, Dawn C Schwenke. Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. Journal of palliative medicine. 2011 Sep; 14(9):1029-33. doi: 10.1089/jpm.2011.0103. [PMID: 21823925]
  • Trine Naalsund Andreassen, Pål Klepstad, Andrew Davies, Kristin Bjordal, Staffan Lundström, Stein Kaasa, Ola Dale. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. European journal of clinical pharmacology. 2011 May; 67(5):493-506. doi: 10.1007/s00228-010-0948-5. [PMID: 21140139]
  • Amadeo Pesce, Cameron West, Robert West, Bridgit Crews, Charles Mikel, Murray Rosenthal, Perla Almazon, Sergey Latyshev. Determination of medication cutoff values in a pain patient population. Journal of opioid management. 2011 Mar; 7(2):117-22. doi: 10.5055/jom.2011.0054. [PMID: 21561035]
  • Irma H Benedek, Janet Jobes, Qinfang Xiang, William D Fiske. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug design, development and therapy. 2011; 5(?):455-63. doi: 10.2147/dddt.s24372. [PMID: 22162639]
  • Timo Korjamo, Ari Tolonen, Veli-Pekka Ranta, Miia Turpeinen, Hannu Kokki. Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance. Frontiers in pharmacology. 2011; 2(?):87. doi: 10.3389/fphar.2011.00087. [PMID: 22291644]
  • Antti Liukas, Kristiina Kuusniemi, Riku Aantaa, Petri Virolainen, Mikko Neuvonen, Pertti J Neuvonen, Klaus T Olkkola. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs & aging. 2011 Jan; 28(1):41-50. doi: 10.2165/11586140-000000000-00000. [PMID: 21174486]
  • Matthew J Geraci, James Peele, Stacey L McCoy, Brad Elias. Phencyclidine false positive induced by lamotrigine (Lamictal®) on a rapid urine toxicology screen. International journal of emergency medicine. 2010 Nov; 3(4):327-31. doi: 10.1007/s12245-010-0235-3. [PMID: 21373301]
  • Shawn P Vorce, Barry Levine, Pamela C McDonough, Marilyn R Past. An overdose death involving the insufflation of extended-release oxymorphone tablets. Journal of analytical toxicology. 2010 Oct; 34(8):521-6. doi: 10.1093/jat/34.8.521. [PMID: 21819798]
  • P V Robandt, H M Bui, J M Scancella, K L Klette. Automated solid-phase extraction-liquid chromatography-tandem mass spectrometry analysis of 6-acetylmorphine in human urine specimens: application for a high-throughput urine analysis laboratory. Journal of analytical toxicology. 2010 Oct; 34(8):470-5. doi: 10.1093/jat/34.8.470. [PMID: 21819792]
  • Tuija H Nieminen, Nora M Hagelberg, Teijo I Saari, Mikko Neuvonen, Pertti J Neuvonen, Kari Laine, Klaus T Olkkola. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. European journal of clinical pharmacology. 2010 Oct; 66(10):977-85. doi: 10.1007/s00228-010-0879-1. [PMID: 20697700]
  • Tuija H Nieminen, Nora M Hagelberg, Teijo I Saari, Mikko Neuvonen, Pertti J Neuvonen, Kari Laine, Klaus T Olkkola. Grapefruit juice enhances the exposure to oral oxycodone. Basic & clinical pharmacology & toxicology. 2010 Oct; 107(4):782-8. doi: 10.1111/j.1742-7843.2010.00582.x. [PMID: 20406214]
  • Juha Grönlund, Teijo I Saari, Nora M Hagelberg, Pertti J Neuvonen, Klaus T Olkkola, Kari Laine. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. British journal of clinical pharmacology. 2010 Jul; 70(1):78-87. doi: 10.1111/j.1365-2125.2010.03653.x. [PMID: 20642550]
  • C F Samer, Y Daali, M Wagner, G Hopfgartner, C B Eap, M C Rebsamen, M F Rossier, D Hochstrasser, P Dayer, J A Desmeules. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. British journal of pharmacology. 2010 Jun; 160(4):907-18. doi: 10.1111/j.1476-5381.2010.00673.x. [PMID: 20590587]
  • Edward J Cone, Anne Zichterman, Rebecca Heltsley, David L Black, Beverly Cawthon, Tim Robert, Frank Moser, Yale H Caplan. Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives. Forensic science international. 2010 May; 198(1-3):58-61. doi: 10.1016/j.forsciint.2009.12.005. [PMID: 20036472]
  • Pedro Boscan, Bruno H Pypendop, Kristine T Siao, Thierry Francey, Kristy Dowers, Larry Cowgill, Jan E Ilkiw. Fluid balance, glomerular filtration rate, and urine output in dogs anesthetized for an orthopedic surgical procedure. American journal of veterinary research. 2010 May; 71(5):501-7. doi: 10.2460/ajvr.71.5.501. [PMID: 20433374]
  • Teijo I Saari, Juha Grönlund, Nora M Hagelberg, Mikko Neuvonen, Kari Laine, Pertti J Neuvonen, Klaus T Olkkola. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. European journal of clinical pharmacology. 2010 Apr; 66(4):387-97. doi: 10.1007/s00228-009-0775-8. [PMID: 20076952]
  • Marie Gingras, Marie-Hélène Laberge, Michel Lefebvre. Evaluation of the usefulness of an oxycodone immunoassay in combination with a traditional opiate immunoassay for the screening of opiates in urine. Journal of analytical toxicology. 2010 Mar; 34(2):78-83. doi: 10.1093/jat/34.2.78. [PMID: 20223099]
  • M Wagner, E Bourgogne, E Varesio, G Hopfgartner. Quantitation of polar analytes using column-switching: application to oxycodone and three metabolites in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2010 Mar; 878(7-8):637-44. doi: 10.1016/j.jchromb.2010.01.014. [PMID: 20138595]
  • Tim Dahn, Josh Gunn, Scott Kriger, Andrea R Terrell. Quantitation of morphine, codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and 6-monoacetylmorphine (6-MAM) in urine, blood, serum, or plasma using liquid chromatography with tandem mass spectrometry detection. Methods in molecular biology (Clifton, N.J.). 2010; 603(?):411-22. doi: 10.1007/978-1-60761-459-3_40. [PMID: 20077093]
  • Rebecca Heltsley, Anne Zichterman, David L Black, Beverly Cawthon, Tim Robert, Frank Moser, Yale H Caplan, Edward J Cone. Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites. Journal of analytical toxicology. 2010 Jan; 34(1):32-8. doi: 10.1093/jat/34.1.32. [PMID: 20109300]
  • Juha Grönlund, Teijo Saari, Nora Hagelberg, Ilkka K Martikainen, Pertti J Neuvonen, Klaus T Olkkola, Kari Laine. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. Journal of clinical pharmacology. 2010 Jan; 50(1):101-8. doi: 10.1177/0091270009336444. [PMID: 19755414]
  • Iain M McIntyre, James L Sherrard, Craig L Nelson. Case report: Oxymorphone-involved fatalities: a report of two cases. Journal of analytical toxicology. 2009 Nov; 33(9):615-9. doi: 10.1093/jat/33.9.615. [PMID: 20040137]
  • Markus Fridén, Susanne Winiwarter, Gunilla Jerndal, Ola Bengtsson, Hong Wan, Ulf Bredberg, Margareta Hammarlund-Udenaes, Madeleine Antonsson. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. Journal of medicinal chemistry. 2009 Oct; 52(20):6233-43. doi: 10.1021/jm901036q. [PMID: 19764786]
  • Ahmed I Al-Asmari, Robert A Anderson, Gail A A Cooper. Oxycodone-related fatalities in the west of Scotland. Journal of analytical toxicology. 2009 Oct; 33(8):423-32. doi: 10.1093/jat/33.8.423. [PMID: 19874648]
  • Lisa Krugner-Higby, Butch KuKanich, Brynn Schmidt, Timothy D Heath, Carolyn Brown, Lesley J Smith. Pharmacokinetics and behavioral effects of an extended-release, liposome-encapsulated preparation of oxymorphone in rhesus macaques. The Journal of pharmacology and experimental therapeutics. 2009 Jul; 330(1):135-41. doi: 10.1124/jpet.108.150052. [PMID: 19351868]
  • Tuija H Nieminen, Nora M Hagelberg, Teijo I Saari, Antti Pertovaara, Mikko Neuvonen, Kari Laine, Pertti J Neuvonen, Klaus T Olkkola. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology. 2009 Jun; 110(6):1371-8. doi: 10.1097/aln.0b013e31819faa54. [PMID: 19417618]
  • Stine T Zwisler, Thomas P Enggaard, Lene Noehr-Jensen, Rasmus S Pedersen, Soeren Mikkelsen, Flemming Nielsen, Kim Brosen, Soeren H Sindrup. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic & clinical pharmacology & toxicology. 2009 Apr; 104(4):335-44. doi: 10.1111/j.1742-7843.2009.00378.x. [PMID: 19281600]
  • Diana Garside, Robert L Hargrove, Ruth E Winecker. Concentration of oxymorphone in postmortem fluids and tissue. Journal of analytical toxicology. 2009 Apr; 33(3):121-8. doi: 10.1093/jat/33.3.121. [PMID: 19371460]
  • Nora M Hagelberg, Tuija H Nieminen, Teijo I Saari, Mikko Neuvonen, Pertti J Neuvonen, Kari Laine, Klaus T Olkkola. Voriconazole drastically increases exposure to oral oxycodone. European journal of clinical pharmacology. 2009 Mar; 65(3):263-71. doi: 10.1007/s00228-008-0568-5. [PMID: 18836708]
  • Christelle Boileau, Johanne Martel-Pelletier, Judith Caron, Philippe Msika, Georges B Guillou, Caroline Baudouin, Jean-Pierre Pelletier. Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. Arthritis research & therapy. 2009; 11(2):R41. doi: 10.1186/ar2649. [PMID: 19291317]
  • Paul Sloan. Review of oral oxymorphone in the management of pain. Therapeutics and clinical risk management. 2008 Aug; 4(4):777-87. doi: 10.2147/tcrm.s1784. [PMID: 19209260]
  • Mikko Neuvonen, Pertti J Neuvonen. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. Therapeutic drug monitoring. 2008 Jun; 30(3):333-40. doi: 10.1097/ftd.0b013e31816e2d4b. [PMID: 18520605]
  • Veronica Santos, Karin Jannet Vera López, Luciana Moraes Santos, Mauricio Yonamine, Maria José Carvalho Carmona, Silvia Regina Cavani Jorge Santos. Determining plasma morphine levels using GC-MS after solid phase extraction to monitor drug levels in the postoperative period. Clinics (Sao Paulo, Brazil). 2008 Jun; 63(3):307-14. doi: 10.1590/s1807-59322008000300004. [PMID: 18568238]
  • Pamela C McDonough, Barry Levine, Shawn Vorce, Rebecca A Jufer, David Fowler. The detection of hydromorphone in urine specimens with high morphine concentrations. Journal of forensic sciences. 2008 May; 53(3):752-4. doi: 10.1111/j.1556-4029.2008.00730.x. [PMID: 18471228]
  • Edward J Cone, Yale H Caplan, Frank Moser, Tim Robert, David Black. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. Journal of analytical toxicology. 2008 May; 32(4):319-23. doi: 10.1093/jat/32.4.319. [PMID: 18430301]
  • Samuel Chan, Stephen R Edwards, Bruce D Wyse, Maree T Smith. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. Clinical and experimental pharmacology & physiology. 2008 Mar; 35(3):295-302. doi: 10.1111/j.1440-1681.2007.04821.x. [PMID: 17973932]
  • Steven C Curry, David J Watts, Kenneth D Katz, Dale Bikin, Bonny L Bukaveckas. The effect of single-dose tramadol on oxycodone clearance. The Journal of emergency medicine. 2007 Nov; 33(4):407-11. doi: 10.1016/j.jemermed.2007.03.042. [PMID: 17976797]